NCT04536792 - A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease | Biotech Hunter

Enrollment

122

Participants

Timeline

Start Date

July 10, 2020

Primary Completion Date

December 19, 2023

Study Completion Date

December 19, 2023

Conditions

Healthy VolunteersAnemia, Sickle Cell

Interventions

DRUG

AG-946

AG-946, oral encapsulated coated-granules or tablets.

DRUG

AG-946 Matched Placebo

AG-946 matched-placebo, oral encapsulated sugar spheres or tablets.

Trial Locations (10)

Rigshospitalet, Department of Hematology, Copenhagen

New York Presbyterian Hospital - Weill Cornell Medicine, New York

University of Pittsburgh Medical Center, Pittsburgh

Texas Oncology-Baylor Charles A. Sammons Cancer Center - USOR, Dallas

University of Texas Health Science Center of Houston, Houston

PPD Development, LP, Austin

University of California San Diego, La Jolla

Massachusetts General Hospital, Boston

Boston Medical Center, Boston

Hospital Universitario Vall d'Hebron - PPDS, Barcelona